Cargando…
Metabolic Disturbances, Side Effect Profile and Effectiveness of Clozapine in Adolescents
INTRODUCTION: Data on effect of clozapine on metabolic syndrome in adolescent patients with psychosis are limited. This study aimed to evaluate the prevalence and incidence of metabolic syndrome in children and adolescents with psychotic disorders prior to clozapine and while receiving clozapine. Se...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904759/ https://www.ncbi.nlm.nih.gov/pubmed/27335518 http://dx.doi.org/10.4103/0253-7176.183091 |
_version_ | 1782437197624901632 |
---|---|
author | Grover, Sandeep Hazari, Nandita Chakrabarti, Subho Avasthi, Ajit |
author_facet | Grover, Sandeep Hazari, Nandita Chakrabarti, Subho Avasthi, Ajit |
author_sort | Grover, Sandeep |
collection | PubMed |
description | INTRODUCTION: Data on effect of clozapine on metabolic syndrome in adolescent patients with psychosis are limited. This study aimed to evaluate the prevalence and incidence of metabolic syndrome in children and adolescents with psychotic disorders prior to clozapine and while receiving clozapine. Secondary aims were to study the effectiveness and side effect profile of clozapine. MATERIALS AND METHODS: Thirteen child and adolescent patients were evaluated at baseline, 3 months, and a follow-up beyond 6 months. Assessments were made for metabolic profile, effectiveness by positive and negative syndrome scale (PANSS), and side effects. RESULTS: Prior to starting of clozapine, the prevalence of metabolic syndrome was 23%. After 3 months on clozapine, 38.5% (5/13) patients fulfilled criteria of metabolic syndrome and further on follow-up beyond 6 months (with last observation carried forward) 46.2% (6/13) had developed metabolic syndrome. There was a significant reduction in PANSS scores at 3 months and follow-up more so in those who developed metabolic syndrome at 3 months. Among the other side effects, hypersalivation was the most common side effect (100%) followed by sedation (69%). CONCLUSION: Half the prevalence of metabolic syndrome in adolescents on clozapine can be attributed to other factors prior to starting of clozapine, and another half can be attributed to clozapine. Clozapine is effective in an adolescent population. |
format | Online Article Text |
id | pubmed-4904759 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-49047592016-06-22 Metabolic Disturbances, Side Effect Profile and Effectiveness of Clozapine in Adolescents Grover, Sandeep Hazari, Nandita Chakrabarti, Subho Avasthi, Ajit Indian J Psychol Med Original Article INTRODUCTION: Data on effect of clozapine on metabolic syndrome in adolescent patients with psychosis are limited. This study aimed to evaluate the prevalence and incidence of metabolic syndrome in children and adolescents with psychotic disorders prior to clozapine and while receiving clozapine. Secondary aims were to study the effectiveness and side effect profile of clozapine. MATERIALS AND METHODS: Thirteen child and adolescent patients were evaluated at baseline, 3 months, and a follow-up beyond 6 months. Assessments were made for metabolic profile, effectiveness by positive and negative syndrome scale (PANSS), and side effects. RESULTS: Prior to starting of clozapine, the prevalence of metabolic syndrome was 23%. After 3 months on clozapine, 38.5% (5/13) patients fulfilled criteria of metabolic syndrome and further on follow-up beyond 6 months (with last observation carried forward) 46.2% (6/13) had developed metabolic syndrome. There was a significant reduction in PANSS scores at 3 months and follow-up more so in those who developed metabolic syndrome at 3 months. Among the other side effects, hypersalivation was the most common side effect (100%) followed by sedation (69%). CONCLUSION: Half the prevalence of metabolic syndrome in adolescents on clozapine can be attributed to other factors prior to starting of clozapine, and another half can be attributed to clozapine. Clozapine is effective in an adolescent population. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC4904759/ /pubmed/27335518 http://dx.doi.org/10.4103/0253-7176.183091 Text en Copyright: © Indian Journal of Psychological Medicine http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution NonCommercial ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Grover, Sandeep Hazari, Nandita Chakrabarti, Subho Avasthi, Ajit Metabolic Disturbances, Side Effect Profile and Effectiveness of Clozapine in Adolescents |
title | Metabolic Disturbances, Side Effect Profile and Effectiveness of Clozapine in Adolescents |
title_full | Metabolic Disturbances, Side Effect Profile and Effectiveness of Clozapine in Adolescents |
title_fullStr | Metabolic Disturbances, Side Effect Profile and Effectiveness of Clozapine in Adolescents |
title_full_unstemmed | Metabolic Disturbances, Side Effect Profile and Effectiveness of Clozapine in Adolescents |
title_short | Metabolic Disturbances, Side Effect Profile and Effectiveness of Clozapine in Adolescents |
title_sort | metabolic disturbances, side effect profile and effectiveness of clozapine in adolescents |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904759/ https://www.ncbi.nlm.nih.gov/pubmed/27335518 http://dx.doi.org/10.4103/0253-7176.183091 |
work_keys_str_mv | AT groversandeep metabolicdisturbancessideeffectprofileandeffectivenessofclozapineinadolescents AT hazarinandita metabolicdisturbancessideeffectprofileandeffectivenessofclozapineinadolescents AT chakrabartisubho metabolicdisturbancessideeffectprofileandeffectivenessofclozapineinadolescents AT avasthiajit metabolicdisturbancessideeffectprofileandeffectivenessofclozapineinadolescents |